Sybil G Hosek1, George Siberry, Margo Bell, Michelle Lally, Bill Kapogiannis, Keith Green, M Isabel Fernandez, Brandy Rutledge, Jaime Martinez, Robert Garofalo, Craig M Wilson. 1. *Department of Psychiatry, John Stroger Hospital of Cook County, Chicago, IL †Maternal and Pediatric Infectious Disease Branch, NICHD/PAMAB, Bethesda, MD ‡Department of Pediatrics, John Stroger Hospital of Cook County, Chicago, IL §Department of Medicine, Alpert Medical School of Brown University, Providence, RI ‖Department of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL ¶Westat, Rockville, MD #Department of Pediatrics, Children's Memorial Hospital, Chicago, IL **Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: This study examined the feasibility of a combination prevention intervention for young men who have sex with men (YMSM), an anticipated target population for HIV preexposure prophylaxis (PrEP). METHODS: Project PrEPare, a pilot study using a randomized 3-arm design, compared an efficacious behavioral HIV prevention intervention (Many Men, Many Voices-3 MV) alone, 3 MV combined with PrEP (tenofovir/emtricitabine), and 3 MV combined with placebo. Eligible participants were 18- to 22-year-old HIV-uninfected men who reported unprotected anal intercourse in the past year. Participants were screened for preliminary eligibility at youth venues and community organizations and were also referred through social networks. Laboratory screening determined final eligibility. Behavioral and biomedical data were collected at baseline and every 4 weeks thereafter for 24 weeks. RESULTS:Sixty-eight youth (mean age = 19.97 years; 53% African American, 40% Latino) were enrolled; 58 were randomized. Self-reported medication adherence averaged 62% (range, 43%-83%), whereas rates of detectable tenofovir in plasma of participants in the emtricitabine/tenofovir disoproxil fumarate arm ranged from 63.2% (week 4) to 20% (week 24). There were 5 ≥ grade 2 adverse events possibly/probably related to the study medication. Sexual risk behavior declined from baseline to week 24 in all study arms. CONCLUSIONS: The feasibility of enrolling at-risk youth, particularly young men who have sex with men of color, into Project PrEPare has been demonstrated. The acceptability of the group intervention along with counseling and testing was high. Self-reported medication adherence and corresponding plasma drug concentrations were low indicating the need for enhanced adherence counseling. Exploration of PrEP use among youth in nonrandomized open label trials is warranted.
RCT Entities:
BACKGROUND: This study examined the feasibility of a combination prevention intervention for young men who have sex with men (YMSM), an anticipated target population for HIV preexposure prophylaxis (PrEP). METHODS: Project PrEPare, a pilot study using a randomized 3-arm design, compared an efficacious behavioral HIV prevention intervention (Many Men, Many Voices-3 MV) alone, 3 MV combined with PrEP (tenofovir/emtricitabine), and 3 MV combined with placebo. Eligible participants were 18- to 22-year-old HIV-uninfectedmen who reported unprotected anal intercourse in the past year. Participants were screened for preliminary eligibility at youth venues and community organizations and were also referred through social networks. Laboratory screening determined final eligibility. Behavioral and biomedical data were collected at baseline and every 4 weeks thereafter for 24 weeks. RESULTS: Sixty-eight youth (mean age = 19.97 years; 53% African American, 40% Latino) were enrolled; 58 were randomized. Self-reported medication adherence averaged 62% (range, 43%-83%), whereas rates of detectable tenofovir in plasma of participants in the emtricitabine/tenofovir disoproxil fumarate arm ranged from 63.2% (week 4) to 20% (week 24). There were 5 ≥ grade 2 adverse events possibly/probably related to the study medication. Sexual risk behavior declined from baseline to week 24 in all study arms. CONCLUSIONS: The feasibility of enrolling at-risk youth, particularly young men who have sex with men of color, into Project PrEPare has been demonstrated. The acceptability of the group intervention along with counseling and testing was high. Self-reported medication adherence and corresponding plasma drug concentrations were low indicating the need for enhanced adherence counseling. Exploration of PrEP use among youth in nonrandomized open label trials is warranted.
Authors: Leo Wilton; Jeffrey H Herbst; Patricia Coury-Doniger; Thomas M Painter; Gary English; Maria E Alvarez; Maureen Scahill; Michael A Roberson; Basil Lucas; Wayne D Johnson; James W Carey Journal: AIDS Behav Date: 2009-03-09
Authors: Albert Y Liu; Nancy A Hessol; Eric Vittinghoff; K Rivet Amico; Elizabeth Kroboth; Jonathan Fuchs; Risha Irvin; R Craig Sineath; Travis Sanchez; Patrick S Sullivan; Susan P Buchbinder Journal: AIDS Patient Care STDS Date: 2014-12 Impact factor: 5.078
Authors: David V Glidden; K Rivet Amico; Albert Y Liu; Sybil G Hosek; Peter L Anderson; Susan P Buchbinder; Vanessa McMahan; Kenneth H Mayer; Burns David; Mauro Schechter; Beatriz Grinsztejn; Juan Guanira; Robert M Grant Journal: Clin Infect Dis Date: 2016-01-20 Impact factor: 9.079
Authors: Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Colleen C Hoff; Deepalika Chakravarty; Anja E Bircher; Chadwick K Campbell; Kirk Grisham; Torsten B Neilands; Patrick A Wilson; Shari Dworkin Journal: AIDS Patient Care STDS Date: 2015-06-09 Impact factor: 5.078